Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results

Blood blood.2024024789.

https://doi.org/10.1182/blood.2024024789

Published: 2024

Includes: Supplemental data

Journal Articles

JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results

Joseph Pidala, Shernan G. Holtan, Kelly Walton, Jongphil Kim, Hany Elmariah, Asmita Mishra, Nelli Bejanyan, Taiga Nishihori, Farhad Khimani, Lia Perez, Rawan Faramand, Marco Davila, Claudio Anasetti, Daniel Weisdorf, Bruce R Blazar, Jeffrey S Miller, Veronika Bachanova, Najla H El Jurdi, Brian C Betts

Blood (2023) 142 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2023-173376

Published: 2023

Journal Articles

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Blood (2022) 140 (Supplement 1): 282–283.

https://doi.org/10.1182/blood-2022-165782

Published: 2022

Journal Articles

Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis

Blood (2021) 138 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2021-147569

Published: 2021

Journal Articles

Validation of Amphiregulin As a Monitoring Biomarker during Treatment of Life-Threatening Acute Gvhd: A Secondary Analysis of 2 Prospective Clinical Trials

Michael A. Pratta, Najla H El Jurdi, Armin Rashidi, Brian C. Betts, John P Galvin, Margaret L. MacMillan, Daniel J. Weisdorf, Angela Panoskaltsis-Mortari, Shernan G Holtan

Blood (2021) 138 (Supplement 1): 259.

https://doi.org/10.1182/blood-2021-150867

Published: 2021

Journal Articles

Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd

Blood (2021) 138 (Supplement 1): 261.

https://doi.org/10.1182/blood-2021-145008

Published: 2021

Journal Articles

Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease

Grigori Okoev, MD PhD, Daniel J. Weisdorf, MD, John E Wagner, MD, Bruce R. Blazar, MD, Margaret L. MacMillan, MD, Todd E. DeFor, MS, Aleksandr Lazaryan, MDPhDMPH, Najla H El Jurdi, MD, Shernan G Holtan, MD, Claudio G. Brunstein, MD PhD, Brian C. Betts, MD, Takuto Takahashi, MD, Veronika Bachanova, MD PhD, Erica D. Warlick, MD, Armin Rashidi, MD PhD, Mukta Arora, MD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-136479

Published: 2020

Journal Articles

High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease

Blood (2020) 136 (Supplement 1): 44–46.

https://doi.org/10.1182/blood-2020-136337

Published: 2020

Journal Articles

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Joseph Pidala, MD, Kelly Walton, Hany Elmariah, MDMS, Jongphil Kim, PhD, Asmita Mishra, MD, Nelli Bejanyan, MD, Taiga Nishihori, MD, Farhad Khimani, MBBS, Lia Perez, MD, Rawan Faramand, MD, Marco L. Davila, MD PhD, Michael Nieder, MD, Nicholas Lawrence, PhD, Harshani Lawrence, PhD, Claudio Anasetti, MD, Said Sebti, PhD, Brian C. Betts, MD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-133874

Published: 2020

Journal Articles

Plasma Short Chain Fatty Acids As a Predictor of Response to Therapy for Life-Threatening Acute Graft-Versus-Host Disease

Parth Gandhi, Isha Gandhi, Andrea Hoeschen, Wes Mosher, Margaret L. MacMillan, MD, Armin Rashidi, MD PhD, Najla H El Jurdi, MD, Alexander Khoruts, MD, Daniel J. Weisdorf, MD, Bruce R. Blazar, MD, Qing Cao, MS, Brian C. Betts, MD, Angela Panoskaltsis-Mortari, PhD, Chi Chen, Shernan G Holtan, MD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-140117

Published: 2020

Journal Articles

Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)

Grigori Okoev, MD PhD, Daniel J. Weisdorf, MD, John E. Wagner, MD, Bruce R. Blazar, MD, Margaret L. MacMillan, MD, Todd E. DeFor, MS, Aleksandr Lazaryan, MDPhDMPH, Najla H El Jurdi, MD, Shernan Holtan, MD, Claudio G Brunstein, MD PhD, Brian C. Betts, MD, Takuto Takahashi, MD, Veronika Bachanova, MD PhD, Erica D. Warlick, MD, Armin Rashidi, MD PhD, Mukta Arora, MD

Blood (2019) 134 (Supplement_1): 2009.

https://doi.org/10.1182/blood-2019-123421

Published: 2019

Journal Articles

Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia

Bishwas Shrestha, PhD, Kelly Walton, Jordan Reff, Elizabeth M. Sagatys, MD, Nhan Tu, PhD, Justin C. Boucher, PhD, Tayyeb Ghafoor, BS, Joseph Pidala, MD, Bruce R. Blazar, MD, Claudio Anasetti, MD, Brian C. Betts, MD, Marco L. Davila, MD PhD

Blood (2019) 134 (Supplement_1): 196.

https://doi.org/10.1182/blood-2019-124031

Published: 2019

Journal Articles

A Phase II Trial Evaluating the Use of the Histone Deacetylase Inhibitor Panobinostat for Graft-Versus-Host Disease (GVHD) Prevention

Lia Perez, MD, Hugo F. Fernandez, MD, Farhad Khimani, MBBS, Ernesto Ayala, MD, Mohamed A Kharfan-Dabaja, MD, Asmita Mishra, MD, Leonel Ochoa, MD, Brian C. Betts, MD, Joseph Pidala, MD PhD, Claudio Anasetti, MD

Blood (2017) 130 (Supplement 1): 1985.

https://doi.org/10.1182/blood.V130.Suppl_1.1985.1985

Published: 2017

Journal Articles

Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS

Ryan James Caddell, PharmD, Braydon Schaible, MPH, Zhenjun Ma, PhD, Elizabeth Dimaggio, PharmD, BCOP, Rebecca Tombleson, PharmD, BCOP, Claudio Anasetti, MD, Ernesto Ayala, MD, Brian C. Betts, MD, Mohamed A. Kharfan-Dabaja, MD, Frederick L. Locke, MD, Taiga Nishihori, MD, Joseph A. Pidala, MD, Hugo F. Fernandez, MD, Asmita Mishra, MD

Blood (2016) 128 (22): 3486.

https://doi.org/10.1182/blood.V128.22.3486.3486

Published: 2016

Journal Articles

Targeting JAK2 By Gene Knockout or Pacritinib Treatment Reduces Gvhd and Xenograft Rejection By Promoting Induced Treg Differentiation

Brian C Betts, MD, David Bastian, Hung Nguyen, PhD, Jessica Lauren Heinrichs, BS, MS, Yongxia Wu, MD PhD, Anandharaman Veerapathran, PhD, Marie C Lee, MD, Jack Singer, MD, Claudio Anasetti, MD, Xue-Zhong Yu, MD MS

Blood (2015) 126 (23): 1874.

https://doi.org/10.1182/blood.V126.23.1874.1874

Published: 2015

Journal Articles

CD4 Treg and CD4 Tcon Utilize Distinct TCR Vbeta Repertoires in Response to Alloantigen

Anandharaman Veerapathran, PhD, Micheal Schell, PhD, Francisca Beato, B.S, TzuHua Juan, MPH, Sean Yoder, M.S, Brian C Betts, MD, Joseph A Pidala, MD, PhD, Claudio Anasetti, MD

Blood (2015) 126 (23): 4286.

https://doi.org/10.1182/blood.V126.23.4286.4286

Published: 2015

Journal Articles

CD4+ T-Cell STAT3 Activity Is Increased before Acute Graft-Versus-Host Disease Onset and Its Pharmacologic Inhibition Selectively Controls Alloresponses

Brian C Betts, MD, Anandharaman Veerapathran, PhD, Francisca Beato, BS, Harshani R Lawrence, PhD, Said M Sebti, PhD, Joseph A Pidala, MD, Claudio Anasetti, MD

Blood (2014) 124 (21): 3819.

https://doi.org/10.1182/blood.V124.21.3819.3819

Published: 2014

Journal Articles

Does HLA-C Matching Predict the Engrafting Unit in Double Umbilical Cord Blood Transplants?: A Single Institution Retrospective Analysis

Michael T Tees, MD MPH, Brian C Betts, MD, Hugo F Fernandez, MD, Ryan Hillgruber, Ernesto Ayala, MD, Teresa Field, MD PhD, Mohamed A Kharfan-Dabaja, MD, Frederick L Locke, MD, Asmita Mishra, MD, Taiga Nishihori, MD, Jose L Ochoa-Bayona, MD, Lia Perez, MD, Joseph Pidala, MD PhD, Claudio Anasetti, MD, Marcie L Riches, MD MS

Blood (2014) 124 (21): 2475.

https://doi.org/10.1182/blood.V124.21.2475.2475

Published: 2014

Journal Articles

A Phase I/II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat (LBH589) in Addition to Glucocorticoids in Patients with Acute Graft-Versus-Host Disease

Lia Perez, MD, Teresa Field, MD PhD, Marcie L Riches, MD MS, Hugo F Fernandez, MD, Frederick L Locke, MD, Brian C Betts, MD, Joseph Pidala, MD PhD, Erika Elmer, CCRP, Francisca Beato, BS, Maritza Lienlaf, MS, Pedro Horna, MD, Alejandro Villagra, PhD, Claudio Anasetti, MD

Blood (2014) 124 (21): 1167.

https://doi.org/10.1182/blood.V124.21.1167.1167

Published: 2014

Journal Articles

Beclomethasone and Budesonide Are Partially Effective As Sole Therapy for Isolated Gastro-Intestinal Gvhd

Chiara Frairia, MD, Jamie Shapiro, PharmD, Jongphil Kim, PhD, Joseph Pidala, MD PhD, Ernesto Ayala, MD, Brian C Betts, MD, Hugo F Fernandez, MD, Teresa Field, MD PhD, Mohamed Kharfan-Dabaja, MD, Frederick L Locke, MD, Asmita Mishra, MD, Taiga Nishihori, MD, Jose L Ochoa-Bayona, MD, Lia Perez, MD, Marcie L Riches, MD MS, Claudio Anasetti, MD

Blood (2014) 124 (21): 2500.

https://doi.org/10.1182/blood.V124.21.2500.2500

Published: 2014

NARROW

JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results

JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis

Validation of Amphiregulin As a Monitoring Biomarker during Treatment of Life-Threatening Acute Gvhd: A Secondary Analysis of 2 Prospective Clinical Trials

Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd

Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease

High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Plasma Short Chain Fatty Acids As a Predictor of Response to Therapy for Life-Threatening Acute Graft-Versus-Host Disease

Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)

Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia

A Phase II Trial Evaluating the Use of the Histone Deacetylase Inhibitor Panobinostat for Graft-Versus-Host Disease (GVHD) Prevention

Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS

Targeting JAK2 By Gene Knockout or Pacritinib Treatment Reduces Gvhd and Xenograft Rejection By Promoting Induced Treg Differentiation

CD4 Treg and CD4 Tcon Utilize Distinct TCR Vbeta Repertoires in Response to Alloantigen

CD4+ T-Cell STAT3 Activity Is Increased before Acute Graft-Versus-Host Disease Onset and Its Pharmacologic Inhibition Selectively Controls Alloresponses

Does HLA-C Matching Predict the Engrafting Unit in Double Umbilical Cord Blood Transplants?: A Single Institution Retrospective Analysis

A Phase I/II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat (LBH589) in Addition to Glucocorticoids in Patients with Acute Graft-Versus-Host Disease

Beclomethasone and Budesonide Are Partially Effective As Sole Therapy for Isolated Gastro-Intestinal Gvhd

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only